Platinum-Induced Peripheral Neuropathy: ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Platinum-induced peripheral neuropathy (PIPN) was a significant challenge in the clinical use of platinum drugs like oxaliplatin and cisplatin for cancer treatment due to the accumulation of platinum in the peripheral nervous system. The generation of reactive oxygen species (ROS) was identified as a primary mechanism of PIPN, and downregulating ROS was considered a feasible approach to alleviate the condition. The review discussed the mechanisms of ROS-related PIPN, including platinum accumulation in the dorsal root ganglia and cellular regulation. It summarized antioxidant therapeutic drugs aimed at reducing ROS overproduction and highlighted the role of nanotechnology in developing nanosystems to prevent and treat PIPN. Future prospects and potential breakthroughs in anti-ROS agents and nanosystems were also briefly discussed.